1, Lei Zhi Group 002398: On September 16, Lei Zhi Group resumed trading in the evening, and its share price rose by 5.08% within 7 days. This year, the increase dropped by-16.29%, and the latest price was 6.69 yuan, up by 3.4%, with a market value of 4.82 billion yuan.
Xiamen Aode Biotechnology Co., Ltd. (holding 13%), a shareholding company, obtained the CE certification of the European Union based on the rare earth nano-probe and the novel coronavirus IgM/IgG antibody instant detection kit.
2. Mei Nian Health 002044: On the evening of September 16, SMS resumed. Today, the share price of Meinian Health rose by 2.3% to 15, with a price of 8.0 1 yuan, and its market value reached 313.53 million.
In April, 2000, it was revealed that the company launched two programs for anti-epidemic screening, among which "novel coronavirus nucleic acid detection program" mainly aimed at virus nucleic acid detection. In addition, the "nucleic acid detection" service launched by Ali Health and Mei Nianda Health Tmall flagship store is true.
3. Hong Qian Pharmaceuticals 002550: On September 6th, Hong Qian Pharmaceuticals opened at 4.37 yuan and closed at 4.43 yuan, up 1.6 1%. The highest price on that day was 4.53 yuan, and the lowest was 4.35 yuan, with a total market value of 5.67 billion.
Hong Qian Pharmaceutical said on the interactive platform that Jinghong Ke Sheng, a holding subsidiary of the company, specializes in the research and development and production of molecular diagnostic reagents. At present, the self-developed COVID-19 antigen detection reagent has been listed in the white list of export epidemic prevention materials of the Ministry of Commerce and started to be sold. In addition, COVID-19 nucleic acid detection kit and fusion antibody detection reagent for judging the effectiveness of COVID-19 vaccination are also under development.
4. anke biotechnology 300009: On September 6th, 65438+ news, anke biotechnology made an opening offer of 12.28 yuan and closed at 12.5438+0 yuan. Within three days, the stock price fell by 1.2%, with a total market value of 20.497 billion yuan.
Note: the leading stock is not fixed, and its position can only be maintained for a period of time. Leading stock refers to the stock that has influence and appeal to other stocks in the same industry in a certain period of time in the stock market, and its ups and downs often play a guiding and exemplary role in the ups and downs of other stocks in the same industry.
5. Zheng Chuan shares 603976:
In 2020, the total revenue was 502 million, a year-on-year increase of-3.67%; The net profit was 53.05 million, up-13.11%year-on-year; The gross profit margin of sales is 25.55%.
As one of the leading enterprises in the pharmaceutical glass bottle bottling industry, it is predicted that there will be a serious shortage of glass bottles for storing COVID-19 vaccines, and the company may benefit.
6. Huachang Chemical 002274:
In 2020, the total revenue was 6.099 billion, up by-3.41%year-on-year; The net profit was 654.38+0.83 billion, a year-on-year increase of-9.39%; The gross profit margin of sales is 9.82%.
In February of 20 years, Nanjing Shihe Gene and Practical Medicine invested by Suzhou Ruihua Investment Partnership successfully developed COVID-19 nucleic acid detection kit.
7. Huace Test 3000 12:
The total revenue in 2020 was 3.568 billion, up by 65,438+02.08% year-on-year; The net profit was 578 million, a year-on-year increase of 265,438+0.25%; The gross profit margin of sales was 49.96%.
The verification result of novel coronavirus (20 19-nCov) nucleic acid detection ability was officially released by Shanghai Clinical Laboratory Quality Control Center. Huace AMP Medical Laboratory, a wholly-owned subsidiary of the company, successfully passed the compliance score of 100%, becoming one of the first third-party medical laboratories in Shanghai to obtain the COVID-19 nucleic acid detection capability certification.